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Abstract
The targeting of HIV-1 using antibodies is of high interest as molecular tools to
better understand the biology of the virus or as a first step toward the design of new
inhibitors targeting critical viral intracellular proteins. Small and highly stable llama-
derived single-domain antibodies can often be functionally expressed as
intracellular antibodies in the cytoplasm of eukaryotic cells. Using a selection
method based on the Sos Recruitment System, a cytoplasmic yeast two-hybrid
approach, we have isolated single-domain antibodies able to bind HIV-1 Vpr and
Capside proteins in the yeast cytoplasm. One anti-Vpr single domain antibody was
able to bind the HIV-1 regulatory Vpr protein in the cytoplasm of eukaryotic cells,
leading to its delocalization from the nucleus to the cytoplasm. To our knowledge,
this is the first description of a functional single-domain intrabody targeting HIV-1
Vpr, isolated using an in vivo cytoplasmic selection method that alleviates some
limitations of the conventional yeast two-hybrid system.
Introduction
Most antibody-based approaches to inhibit HIV-1 replication aim at neutralizing
HIV-1 entry by targeting the Env protein [1], but many other HIV-1 proteins
such as reverse transcriptase, integrase and protease enzymes, are efficient
therapeutic targets, as demonstrated by their successful targeting by small
inhibitor molecules used in infected patients in highly active antiretroviral therapy
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(HAART) [2]. These small molecules can efficiently bind the ligand binding site of
their target, thereby inhibiting their function. However, while introduction of
HAART have largely increased the survival time of HIV-1-infected patients, these
therapies are unable to accomplish virus eradication in infected patients,
indicating that targeting of other original viral determinants directly involved in
HIV infection pathogenesis may have high beneficial impact, if combined with the
current HAART regimens [3]. Protein-protein interactions represent major
potential drug targets but these are unanimously difficult to consider with small
chemical molecules. On the other hand, antibodies (Abs) are intrinsically
endowed with the ability to interfere with a given protein-protein interaction
[4, 5]. Unfortunately, most conventional Abs or their fragments, such as single-
chain Fv fragments (scFvs), are not suitable for intracellular expression because
their correct folding and stability generally depend on the formation of an
intradomain disulfide bond, which cannot be efficiently formed in the reducing
environment of the cytoplasm. Indeed, it has been shown that the stability of
intrabodies is directly correlated to their performance when used as cytoplasmic
inhibitors [6]. Few studies could isolate sufficiently stable scFv to demonstrate the
feasibility of this approach to target HIV-1 proteins using anti-Tat or anti-Matrix
scFvs [7, 8]. Single-domain antibodies (sdAbs), derived from heavy-chain
immunoglobulins of Camelidae, are small (13 kDa) and highly stable antibody
fragments that bind their target with high specificity and affinity in the nanomolar
range [9–11]. Most of them can be functionally expressed into the cytoplasm [12–
17] suggesting that disulfide bond formation is often not necessary to maintain
their activity. As such they represent a rich source of functional intrabodies.
Recently, we, and others, have used this property to isolate intrabodies against
HIV-1 Nef and Rev proteins [18, 19] inhibiting most of the functions of these viral
proteins.
One way to favor the efficient selection of functional intrabodies would be to
perform their selection in an environment mimicking the cytoplasm of eukaryotic
cells, unlike conventional methods such as phage display or ribosome display
performed in vitro. To this aim, approaches based on yeast two-hybrid technology
(Y2H) might be of special interest [20–22]. The conventional Y2H is based on a
transcriptional readout where interaction between the bait and prey occurs in the
yeast nucleus. Another advantage of in vivo selection methods such as Y2H is the
absence of requirement for purified antigen, which can be tedious and time
consuming to produce for in vitro selection approaches. However, despite its
successfully use in many studies, conventional Y2H does suffer from some
limitations. Indeed, interactions that involve transcriptional activators or
repressors cannot be performed, and some proteins are toxic to yeast when
targeted to the nucleus [23]. More generally, certain proteins may function more
physiologically when expressed in the cytoplasm rather than in the nuclear milieu.
To overcome these limitations, an alternative approach, named Sos Recruitment
System (SRS), has been developed. SRS is a particular Y2H in which the
interaction between bait and prey happens into the cytoplasm [24], alleviating
several shortcomings of the conventional Y2H.
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In this study, we provide a proof of concept of the feasibility to use SRS to
isolate functional intrabodies targeting HIV-1 viral protein R (Vpr) and HIV-1
capsid (CA). Vpr is a viral accessory protein which disturbs many cellular
pathways by interacting with cellular and viral proteins. Vpr is critical for efficient
virus replication in macrophages, which are known to participate in virus
dissemination and establishment of persistent virus reservoirs in different host
tissues [25, 26]. CA is a part of the Gag polyprotein precursor and is crucial for the
correct assembly of an infectious virion. CA is also involved in the decapsidation
step, the reverse transcription and should also be involved, as well as Vpr, in the
intracytoplasmic transport and nucleus import of the viral DNA [27, 28].
Materials and Methods
Immunization and phage display library construction
Two llamas were immunized with either a synthetic Vpr peptide
(MEQAPEDQGPQREPYNDWTLELLEELKNEAVRHFPRIWLHSLGQHIYETYG-
DTWTGVEALIRILQQLLFIHFRIGCRHSRIGIIQQRRTRNGASKS) or recombi-
nant CA produced in E. coli and purified via its GST Tag which was eliminated by
thrombin cleavage. Using total RNA purified from llama PBMCs, single-domain
antibody genes were amplified by RT-PCR and cloned into the pHEN1 phagemid
as described [29, 30].
Subcloning into pMyr vector
pMyr vector (CytoTrap Two-Hybrid System, Agilent technology) was modified by
QuikChange to add SfiI and NotI restriction sites using primer newmyrfor
(AATTTGCGGCCCAGCCGGCCCTCGTGATCAAACGGGCGGCCGCCG) and
newmyrrev (TCGACGGCGGCCGCCCGTTTGATCACGAGGGCCGGCTGG-
GCCGCA) following the manufacturer’s instructions. The resulting pMyr Sfi-Not
was checked by sequencing and pHEN1 libraries were then subcloned into this
vector using these restriction sites, as described [29], yielding pMyr-sdAb libraries.
Cloning of vpr and CA genes into pSos
Vpr sequence was amplified by PCR from the pLEX-vpr plasmid using primers
sosforvpr (AGTAGGATCCCCATGGAACAAGCCCCAGAAG) and sosrevvpr
(TAATTAACCGCGGCGGCCGCTAGGATCTACTGGCTC CATTTC). CA
sequence was amplified by PCR from the pLEX p24 CA plasmid using primers
sosforCA (AGTAGGATCCCCATGGTACATCAGGCCATATCACC) and
sosrevCA (TAATTAACCGCGGCGGCCGCTAC ATTGCTTCAGCCAAAAC).
The amplified fragments were subcloned into vector pSos by classical NcoI and
NotI digestion and ligation. Clones were verified by sequencing.
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Yeast Two-hybrid system - Sos Recruitment System (CytoTrap)
pSos-CA and pSos-Vpr were used as bait to screen the corresponding pMyr-sdAb
libraries. The GAL1 promoter in the pMyr vector is repressed when glucose is
used as a carbon source and quickly induced in the presence of galactose. Co-
transfections were performed into the temperature-sensitive mutant
Saccharomyces cerevisiae strain cdc25Ha (Agilent technology) using the standard
lithium acetate method [31]. Negative controls were performed by using pSos-
Vpr or pSos-CA and empty pMyr or irrelevant pMyr-Lam or pMyr-MAF-B
vectors, and positive control was performed by using pMyr-Sos Binding protein
(pMyr-SB) (Agilent technology). Resulting transformants were grown for 3 days
at permissive temperature (24 C˚) onto selection medium containing glucose and
additional supplements excluding leucine and uracil (SC-Leu–Ura) to select co-
transfected yeast colonies. After replica-plating onto selective minimal galactose
plates, colonies that showed growth under restrictive temperature (37 C˚) were
considered positive clones (selection step). Next, selected colonies were picked on
glucose containing medium and grown at 24 C˚ for 2 days (amplification step).
They were then replica-plated onto glucose or galactose plates and grew at 37 C˚
(primary screening). To exclude false positives due to revertants, colonies which
grew only onto galactose (inducing media) and not onto glucose plates were
picked. This result was confirmed by a second round of screening performed on
positive colonies by diluting them into 50 ml of sterile H2O and spotting 2 ml of
each suspension onto glucose and galactose plates and incubated at 37 C˚ (drop
assay corresponding to a secondary screening). Colonies which grew onto
galactose but not onto glucose plates were chosen as positive clones. DNA
extraction of positive clones were done as described [31]. The extracted vector was
used to transform bacteria for further amplification and sequenced.
Drop Assay confirmation after fresh transformation
To further confirm the activity of each sequenced clone, a new drop assay was
carried out using freshly transformed yeast. pMyr vectors encoding sequenced
positive clones was used to co-transform the cdc25Ha yeast strain with the
appropriate pSos vector. For each transformation, 3 colonies were diluted into
50 ml of sterile H2O and 2 ml of each suspension was spotted onto glucose and
galactose plates and incubated at 37 C˚. Controls were performed using pSos-Nef,
pSos-Vpr and pSos-CA with pMyr-VHH19 (VHH19 is an anti-Nef sdAb described
previously [18]), pMyr-sdAb aCA2 (selected by phage display), an empty pMyr
vector and pMyr-SB.
Subcloning into pET vector for cytoplasmic expression
For cytoplasmic expression in E. coli, sdAb genes were subcloned into the
pET-AviHis plasmid by using the InFusion kit (Clontech). Briefly, pET-AviHis
was digested by NotI and NcoI enzymes, genes were amplified with
pHENpETaviRev (CGTTCAGACCTGCGGCCGCTGAGGAGACAGTGA-
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CCTGG) and pHENpETaviFor primers (CTTTAAGAAGGAGATATACCA-
TGGCCGAGGTGCAGCTGGTG) and subclonings were performed by recombi-
nation, in accordance with the manufacturer’s indication. Clones were verified by
sequencing.
sdAb production and purification
E. coli BL21DE3 was transformed with pET vectors. Isolated colonies were used to
inoculate 3 ml of 2YT broth containing 100 mg/ml Amp and 2% glucose that were
incubated for 4 h at 37 C˚ with agitation. These precultures were poured into
100 ml of 2YT containing 100 mg/ml Amp and shaked at 37 C˚ until OD600nm of
0.5 was reached. Then, 0.1 mM IPTG were added and temperature was decreased
to 30 C˚ and shaked overnight. Bacteria were pelleted and lyzed using BugBuster
(Novagen) with lysozyme and benzonase. After centrifugation, the soluble fraction
was purified by affinity on Talon beads (Clontech). Buffer was changed for PBS
and proteins were concentrated using Vivaspin column (GE Healthcare).
Concentration determination was done using Bradford protein assay
(BioRad kit).
ELISA assay
Maxisorp plates were coated with 10 mg/ml of GST-CA, GST-MA or Vpr at 4 C˚,
overnight. Plates were saturated with 2% milk-PBS for 1 h. sdAbs Vpr1A and
Vpr2A were added at 50 and 5 mg/ml and sdAbs CA7A and CA8B were added at
90 or 9 mg/ml for 1 h. sdAb aCA2 was used as positive control (50 mg/ml) and
sdAb was omitted as negative control. After three 0.1% Tween-PBS (T-PBS)
washes and three PBS washes, mouse anti-His6 antibody was added for 1 h. After
another T-PBS and PBS washing, HRP-coupled anti-mouse antibody was added
for 1 h. Revelation was done using ABTS. ODs at 450 nm were measured using a
Tecan device.
Subcloning into cell expression vector
SdAb genes and sequences coding for c-myc and His6 tags were amplified by PCR
and subcloned into XhoI sites of pcDNA3.1 vector (Invitrogen). Plasmid encoding
green fluorescent proteins (GFP) and hemaglutinin (HA)-tagged HIV-1 VprLAI
have been described previously [32].
Cell culture
Hela-CD4 cell lines (TZM cells) were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum and antibiotics at
37 C˚ in a humid atmosphere containing 5% CO2.
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ImmunoFluorescence (IF)
250,000 HeLa cells were plated in 6-well plates containing 2 coverslips and were
co-transfected with Fugene (Roche) the day after with 2 mg of plasmids coding
either Vpr-GFP or Gag-GFP and 2 mg of the vector coding for one of the different
sdAbs as recommended by the manufacturer. 24 h after transfection, cells were
fixed with 4% paraformaldehyde for 20 min on ice. Cells were washed 3 times
with PBS/BSA and stained with mouse anti-c-myc antibody 9E10 (1/2000, Roche)
in PBS/BSA supplemented with Triton X-100, 0.1% (Sigma-Aldrich) during
1 hour on ice. After another PBS/BSA washing, 1/250 dilution of goat anti-mouse
conjugated-AlexaFluor555 (Molecular probes, Invitrogen) was added for 1 hour
on ice and washed again with PBS. Cells were plated on microscope slides in a
PBS-glycerol mix (50:50) using the SlowFade Light Antifade Kit containing DAPI
(Molecular probes, Invitrogen). Cells were imaged using a spinning disk confocal
imaging system (CSU-X1M1, Yokogawa) based on an inverted microscope (Leica
DMI6000) with a CoolSnap HQ2 camera (Photometrics) with a 1006 HCX PL
APO objective. The acquisition of images was done with MetaMorph 7.5
(Molecular Devices). The coefficient of Pearson which illustrates the co-
localization ratio has been calculated using the Fiji software.
To confirm results with sdAb Vpr1A, the same experiment was done with
different ratios (1:1, 2:1 and 4:1) of sdAb Vpr1A and HA-Vpr vectors with
additional steps of antibody incubations with the rat anti-HA 3F10 monoclonal
antibody (1/300, Roche) for 1 hour followed by goat anti-rat conjugated-
AlexaFluor488 (1/250, Molecular probes, Invitrogen) for 1 h.
To further study sdAbs CA7A and CA8B, the same experiment was performed
with a HA-CA construction. Cells were treated in the same way as the ones
transfected with HA-Vpr. Plasmid coding for HA-CA was a kind gift of Dr E. Le
Rouzic (Cochin Institute, Paris, France).
Cell cycle analysis
56106 HeLa cells were transfected by electroporation (200V/950mF) with 5 mg of
the GFP expression plasmid, 8 mg of the plasmid encoding HA-Vpr and different
amounts of the sdAb-Vpr1A plasmid. 26106 transfected cells were plated for cell
cycle analysis while 36106 cells were plated for immunoblotting analysis. Two
days later, cells were fixed for 15 min in 1% PFA, permeabilized in cold ethanol
for 1 h at 4 C˚, resuspended in PBS containing 200 mg/ml RNase and 50 mg/ml
propidium iodide (PI), and incubated for 15 min at room temperature prior to
analysis of DNA content by flow cytometry as described previously [33], on a
minimum of 5,000 GFP-positive cells using a Cytomics FC 500 instrument
(Beckman Coulter). The G2 arrest activity was evaluated using the FlowJo
software and we quantified the cells in the different cell cycle phases using the
Dean-Jett-Fox model [34].
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Apoptosis assay
156105 HeLa cells were plated in 6-wells plates and transfected with 1.3 mg of
GFP expression plasmid, 2 mg of the plasmid encoding HA-Vpr and different
amounts of the plasmid encoding sdAb Vpr1A. The apoptosis assay was
performed three days after transfection, cells were assayed for cell surface exposure
of phosphatidylserines (PS) using the PE AnnexinV Apoptosis Detection kit 1
from BD Pharmingen, as recommended by the manufacturer, and analyzed by
flow cytometry on a minimum of 5,000 GFP-positive cells using a Cytomics FC
500 instrument (Beckman Coulter).
Results
Our goal was to isolate llama derived single-domain antibodies (sdAbs) against
HIV-1 Vpr and CA proteins. Our first attempt was to immunize llamas with
recombinant antigens and to isolate sdAbs using a well established phage display
procedure [29, 30] on plastic or bead-immobilized antigens. Two llamas were
immunized with a 96 amino acid-long synthetic polypeptide corresponding to the
full length Vpr proteins or a recombinant CA protein produced in E. coli. The
corresponding phage display libraries built using sdAb genes amplified by RT-
PCR from llama PBMCs and based on pHEN1 phagemid vector had a diversity of
56107 and 1.36107 clones for Vpr and CA, respectively. Classical phage display
enrichment procedures performed on synthetic Vpr peptide adsorbed on plastic
or covalently bound to magnetic beads did not lead to specific binders. Similar
selection procedures performed on recombinant CA were successful, and the
sequencing of positive binders revealed a unique clone, called sdAb aCA2
(unpublished results).
Consequently, we decided to compare the selection efficiency using this time a
cytoplasmic yeast two-hybrid approach named Sos Recruitment System (Fig. 1A).
This approach does not rely on the integrity of a purified antigen and circumvents
possible conformation issues of immobilized antigens during phage display
selections. The two llama sdAb libraries were thus subcloned into pMyr vector
(CytoTrap SRS system), yielding 96107 and 3.36107 colonies, thereby preserving
most of the initial library diversities.
In vivo selection in yeast by Sos Recruitment System
Large preparation of the corresponding pMyr vector libraries were performed and
used for yeast co-transformation experiments with pSos vectors encoding the
fusion of human Sos to the corresponding Vpr or CA antigen as baits. 107 and
1.46106 yeast colonies clones were obtained using Vpr or CA, respectively, after
incubation at 24 C˚ (Table 1). The sizes of these new libraries were found
satisfactory as they correspond to immunized animals.
The selection round yielded 850 and 475 positive clones for Vpr and CA,
respectively. A screening step based on the same interaction (see materials and
A Single-Domain Intrabody Targeting HIV-1 Vpr Protein
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methods for details) decreased the number of positive clones to 13 and 2 positives
clones for Vpr and CA, respectively (Table 1). During a second screening step
based on a more stringent drop assay, two anti-Vpr colonies were found to be
false positives, decreasing the number of candidate to 11 for Vpr and 2 for CA.
The pMyr vectors of these clones were purified and sequenced. The anti-Vpr
clones yielded two unrelated sequences named Vpr1A and Vpr2A. The two anti-
CA clones, named CA7A and CA8B, share their CDR1 and CDR2, but show some
differences in the sequence and length of their CDR3 (Fig. 1B).
Drop Assay after fresh transformation
To confirm these interactions and further establish the specificity of these sdAbs,
each clone was submitted to a new drop assay based on freshly transformed yeasts,
using Vpr, CA or an empty pSos vector as negative control. The interaction
between Nef and an anti-Nef sdAb (VHH19) was used as positive control in this
assay. A pMyr vector coding for a Sos binding protein, able to interact with any
Figure 1. Selection system principle and sequences of selected binders. A) Representation of the Sos
Recruitment System principle. The antigen (Ag) is fused to the human Sos protein (hSos) while sdAbs are
fused to a myristoylation signal anchoring them in the plasma membrane. If the sdAb binds its Ag, hSos is
driven to the membrane and activates the Ras pathway, leading to the growth of cdc25H mutant yeast at non-
permissive temperature. B) Sequences of clones isolated by the SRS technique. Two anti-Vpr and 2 anti-CA
sdAbs were isolated by SRS. The sequences of their 3 complementary determining regions (CDRs) are
shown. The frequency of each clone in the selection output (Freq.) is also reported.
doi:10.1371/journal.pone.0113729.g001
Table 1. Number of clones at each step of the selection process.
Diversity of bacteria
libraries
Number of yeast
transformants
Number of selected clones: selection/primary
screening/secondary screening
Number of clones after
sequencing
Vpr 96107 107 850/13/11 2
CA 3.36107 1.46106 475/2/2 2
doi:10.1371/journal.pone.0113729.t001
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hSos fusion was used to ensure the expression of each fusion protein (Table 2). As
expected, co-transformations of pMyr-Vpr1A and pMyr-Vpr2A with pSos-Vpr
led to yeast colonies onto galactose medium but not onto glucose plate at non-
permissive 37 C˚ temperature, as did co-transformation of pMyr-CA7A and pMyr-
CA8B with pSos-CA, as well as pMyr-VHH19 and pSos-Nef. All pSos plasmids led
to colonies when co-transformed with pMyr-SB. No other interaction was
detected on galactose plate, establishing the specificity of these interactions.
Interestingly sdAb aCA2, selected by phage display, was not able to interact with
hSos-CA in this setting.
Purification from the cytoplasm of E. coli
Such sdAbs capable of functional binding in the cytoplasm of yeast should also be
produced in a soluble form in the cytoplasm of E. coli, where overexpressed but
unfolded proteins usually form insoluble inclusion bodies. The four sdAbs were
thus produced in the cytoplasm of E. coli and purified from the soluble fraction
using metal affinity chromatography. All sdAbs could be easily produced and
purified, reaching production yields of 38, 32, 35 and 30 mg/L of culture for
Vpr1A, Vpr2A, CA7A and CA8B, respectively. Fig. 2A shows the analysis of the
different fractions for sdAb Vpr1A. Interestingly, no difference of migration was
observed in the presence or absence of b-MercaptoEthanol (bME), suggesting that
no disulfide bond was formed. Overall, these successful purifications indicate that
these sdAbs can remain soluble when expressed at high yield in the reducing
environment of the E. coli cytoplasm. The purified sdAbs were assayed for binding
to recombinant GST-CA, GST-MA and synthetic Vpr by ELISA, despite some
concerns about possible changes of antigen confirmation induced by direct
adsorption on plastic, that could be detrimental to the binding of conformation-
sensitive binders. sdAb Vpr1A was found positive and specific for Vpr,
confirming the Y2H result, whereas Vpr2A was found negative in this setting
(Fig. 2B). sdAbs CA7A and CA8B were also found positive and specific for CA in
this assay.
Table 2. Drop assay after fresh transformation.
pMyr SB VHH19 aCA2 CA7A CA8B Vpr1A Vpr2A Empty
pSos +++ - - - - - - -
pSos-Nef +++ +++ - - - - - -
pSos-Vpr +++ - - - - +++ + -
pSos-CA +++ - - + + - - -
Yeast co-transfected with either pSos-Nef, pSos-Vpr or pSos-CA or pSos (empty vector) and either pMyr-VHH19 (an anti-Nef sdAb previously described),
pMyr-aCA2 (selected by phage display), pMyr (empty), pMyr-SB (Sos binding protein), or pMyr plasmids coding for Vpr1A, Vpr2A, CA7A or CA8B were
resuspended and spotted onto galactose or glucose plates. Growth of colonies on galactose plates was indicated by + or - according with number and size
of colonies.
doi:10.1371/journal.pone.0113729.t002
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Colocalization experiments by immunofluorescence
To be used as intrabodies, these sdAbs must be able to bind their target in
eukaryotic cells. To evaluate this possibility, the genes coding for these sdAbs
fused to a c-myc epitope at their C-terminus were subcloned into pcDNA3 and
co-transfected together with HA-tagged or GFP fusions of the viral targets. The
sdAb expression and cellular localization was followed using an anti-c-myc tag
monoclonal antibody. sdAbs CA7A and CA8B were properly expressed and
equally distributed between cytoplasm and nucleus (Fig. 3A). When co-expressed
with HA-CA, which mainly localized in the nucleus, sdAbs CA7A and CA8B
showed a significant co-localization with CA in the nuclear compartment
Figure 2. sdAb biochemical characterization. A) Purification of sdAbs produced into the cytoplasm of E.
coli. SDS-PAGE gel analysis was performed using comparable amount of sample for each step of the
hexahistidine tag based purification process. Molecular weights (MW) are indicated. Soluble fraction of the
total lysate (T), flow through (FT), washes (W) and elution fraction (E) were loaded in the presence or absence
of b-mercaptoethanol (bME). Depicted results corresponding to sdAb Vpr1A are representative of what was
obtained for other clones. B) ELISA assay with purified sdAbs. ELISA was performed by coating Maxisorp
plates ON at 4˚C with 10 mg/ml of GST-CA, GST-MA or Vpr. sdAbs were added at indicated concentrations
(mg/mL). sdAb aCA2 was used as positive control (50 mg/ml) and the absence of sdAb was used as negative
control.
doi:10.1371/journal.pone.0113729.g002
A Single-Domain Intrabody Targeting HIV-1 Vpr Protein
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Figure 3. Immunofluorescence assay using Gag-GFP, HA-CA and sdAbs CA7A and CA8B into HeLa cell. Immunofluorescence was performed by co-
transfecting HeLa cells with a plasmid bearing HA-CA gene (B) or Gag-GFP gene (C) and a plasmid bearing a sdAb gene as indicated. Gag-GFP was
tracked by GFP fluorescence. HA-CA was tracked using an anti-HA rat monoclonal antibody followed by an anti-rat monoclonal antibody coupled to
AlexaFluor488 (green). SdAbs were detected using a mouse anti-c-myc monoclonal antibody followed by an anti-mouse antibody coupled to AlexaFluor555
(red). Fig. 3A are control cells transfected with the sdAb alone. Fig. 3B show cells transfected with HA-CA and Fig. 3C cells transfected with Gag-GFP. The
coefficient of Pearson (coefficient of co-localization) was calculated for each co-transfected cell.
doi:10.1371/journal.pone.0113729.g003
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(Fig. 3B), as indicated by calculation of the Pearson’s coefficient (r50.76 and
0.74, respectively). However, they poorly co-localized with Gag-GFP which was
mainly localized at the cell periphery (Fig. 3C, r50.23 and 0.30).
Similarly anti-Vpr sdAbs were properly expressed and were distributed between
the cytoplasm and the nucleus of cells (Fig. 4A). In the absence of sdAbs, Vpr-
GFP was localized in the nucleus and also concentrated at the nuclear envelope
(see Fig. 4B). The presence of sdAb Vpr2A did not have any effect on the nuclear
localization of Vpr-GPF (Fig. 4B, right column). Indeed, the sdAb was not
detected in the nucleus, indicating that this clone was not able to bind Vpr in this
setting. This result is in agreement with in vitro ELISA results shown in Fig. 2B.
Conversely, the presence of sdAb Vpr1A led to a major delocalization of Vpr-GFP
in the cytoplasm compartment (Fig. 4B, middle column). Vpr-GFP and sdAb
Vpr1A showed a high degree of co-localization, as illustrated by the Pearson’s
coefficient (r50.83), implying that the sdAb was able to sequestrate a very
significant part of Vpr-GFP in the cytoplasm, thereby severely reducing its
concentration in the nucleus.
To rule out any artifact that might be generated by the presence of GFP, and to
define more precisely the effect of sdAb Vpr1A, a similar experiment was
performed in cells co-expressing sdAb Vpr1A and Vpr fused to the small HA
epitope tag (HA-Vpr) for detection (Fig. 4C). In the absence of sdAb Vpr1A, HA-
Vpr was strictly localized in the nucleus (Fig. 4C, first column). When expressed
in the presence of SdAb Vrp1A, HA-Vpr was found co-localized with the sdAb in
the cytoplasm and in the nucleus, independently of the amount of sdAb coding
plasmid used for transfection (Fig. 4C). This observation confirmed that anti-Vpr
sdAb Vpr1A can efficiently bind its antigen in the eukaryotic cytoplasm
environment. Moreover this interaction clearly interferes with Vpr cellular
localization.
Vpr-induced cell cycle arrest and apoptosis
Since the G2-arrest activity and apoptosis induction are the main documented
functions of Vpr ([35] for review), we wanted to evaluate whether intracellular
sdAb Vpr1A could interfere with the cytostatic and apoptotic effects mediated by
Vpr. First, we studied the cytostatic activity of Vpr leading to an arrest of the cell
cycle in the G2 phase. HeLa cells were co-transfected with plasmids encoding for
HA-Vpr and c-myc-tagged sdAb-Vpr1A together with a GFP expression vector,
and the DNA content was analyzed 48 h later by flow cytometry on GFP-positive
cells after staining with propidium iodide. The DNA content profiles of
transfected cells from a representative experiment is shown in Fig. 5A, and the
results of 3 independent experiments are shown in Fig. 5B. In the absence of sdAb
Vpr1A, efficient G2-arrest was measured in cells co-expressing HA-Vpr and GFP,
as evidenced by the net increase of the G2M/G1 ratio compared to cells expressing
GFP alone (Fig. 5B). However, when cells were co-transfected with increasing
amount of the sdAb-Vpr1A expression plasmid, no apparent inhibition of the G2-
A Single-Domain Intrabody Targeting HIV-1 Vpr Protein
PLOS ONE | DOI:10.1371/journal.pone.0113729 December 1, 2014 12 / 19
Figure 4. Immunofluorescence assay using Vpr-GFP, HA-Vpr and sdAbs Vpr1A and Vpr2A. Immunofluorescence was performed by cotransfecting Hela
cells with a plasmid coding for Vpr-GFP (B) or HA-Vpr (C) and increasing amount of a plasmid coding for a sdAb. Vpr-GFP, HA-Vpr and sdAbs were tracked as
described in Fig. 3. The coefficient of Pearson (coefficient of co-localization) was calculated for each cell cotransfected with Vpr-GFP and a sdAb.
doi:10.1371/journal.pone.0113729.g004
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Figure 5. Impact of sdAb-Vpr1A on the G2-arrest and pro-apoptotic activities of Vpr. HeLa cells were co-transfected with plasmids for expression of GFP
and HA-Vpr in combination with increasing concentrations of c-myc tagged sdAb Vpr1A expression plasmid when indicated. (A, B) Cell cycle analysis. 48 h
after transfection, cells were fixed, permeabilized, and stained with propidium iodide. The DNA content was analyzed by flow cytometry on GFP-positive cells.
InA, the cell DNA content profiles from a representative experiment are shown. The cells in G1, S andG2/M phases are indicated on the upper right panel. InB,
results are expressed as the percentage of the G2M/G1 ratio relative to that measured in cells expressing HA-Vpr alone and are the means of 3 independent
experiments. Error bars represent 1 S.D. from themean. Statistical significancewas determined using students t test (n.s., p.0.05; *, p,0.05).C)Pro-apoptotic
activity. 72 h after transfection, cell surface PS exposure was analyzed by flow cytometry on GFP positive cells after staining with phycoerythrin-labelled
Annexin Vand 7AAD (7-Aminoactinomycin). Results are expressed as the percentage of GFP-positive cells displaying surface PS exposure5 relative to cells
expressing HA-Vpr alone, and are themeans of 3 independent experiments. Error bars represent 1 S.D. from themean. Statistical significance was determined
using students t test (n.s., p.0.05; *, p,0.05; **, p,0.01;***, p,0.001). D) Expression of Vpr and sdAb Vpr1A proteins. Lysates from HeLa transfected cells
were analyzed by Western blotting using anti-HA (upper panel), anti-c-myc (middle panel) and anti-b-actin antibodies.
doi:10.1371/journal.pone.0113729.g005
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arrest induced by HA-Vpr was observed, even though sdAb Vpr1A was correctly
expressed in co-transfected cells (Fig. 5D).
The potential effect of sdAb Vpr1A on the Vpr proapoptic activity was then
assayed, 72 h after transfection, by flow cytometry analysis of the cell surface
exposure of phosphatidylserine (PS) after staining with phycoerythrinlabeled
Annexin V (Fig. 5C). As expected, Vpr expression led to an increase of apoptotic
cells but the co-expression of sdAb-Vpr1A had no inhibitory activity on the Vpr-
induced apoptotic effect. Altogether, the results reported in Fig. 5 indicate that,
despite its strong effect on Vpr localization, sdAb Vpr1A has no effect on these
two main Vpr functions.
Discussion
In this study, we used an alternative yeast two-hybrid system to select single-
domain antibodies able to properly fold and bind their antigen in the yeast
cytoplasm. The so-called Sos Recruitment System was used to isolate binders from
two libraries of sdAbs built from the blood of two llamas immunized with either a
recombinant HIV-1 capsid protein or a synthetic HIV-1 Vpr peptide. Two sdAbs
could be selected for each target. An independent in vitro assay using purified
sdAbs on purified antigens adsorbed on plastic confirmed the interaction for one
sdAb for Vpr and two sdAbs for CA. Finally, immunofluorescence was used to
demonstrate that anti-CA sdAbs could partly co-localize with their target in cells,
while the Vpr binder was able to significantly alter the cellular localization of its
antigen.
In vitro phage display selections on immobilized recombinant CA protein
selected a single sdAb (aCA2). The same sdAb library subjected to the in vivo Y2H
selection procedure yielded two other clones, CA7A and CA8B, that were not
found in the phage selection output. Interestingly, aCA2 selected by phage display,
i.e. for its ability to bind its antigen in regular conditions, was found negative
when tested as intrabody in the Y2H assay. These results highlight the fact that a
selection method should ideally be adapted to the final use intended for the
selected binders. Unfortunately, none of the two capsid binders, interacting
properly with CA in the yeast cytoplasm, was found able to interact with a GFP
fusion of the Pr55Gag precursor. It cannot be ruled out that these sdAbs are
simply not functional when expressed in the cytoplasm of eukaryotic cell. Another
explanation might be that the epitope targeted by these sdAbs on the mature
capsid is not accessible in the Pr55Gag polyprotein before the proteolytic
maturation process. This second explanation is supported by the results obtained
when sdAbs CA7A and CA8B were co-expressed with the HA-tagged form of CA,
leading to a to significant co-localization of both sdAbs and HA-CA in the
nucleus, thereby demonstrating a binding activity. Since the maturation step of
Pr55Gag takes place in a late stage of the replication process [27], it would have
been more relevant to directly select for Gag binders. Unfortunately, sufficient
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amounts of a recombinant and purified Pr55Gag polyprotein was not available for
the immunization step.
Vpr is a small protein which is also difficult to produce recombinantly but
which can be obtained by peptide synthesis. However, the structure of such a
peptide might be different from the native peptide. In fact several conformations
might be present in such sample. Phage display selection did not yield any binder,
which might be related to this issue or to more trivial issues such as the adsorption
efficiency of Vpr on solid surface during panning and screening steps. On the
other hand, two binders were selected in vivo by Y2H, and one of these binders
was positive by ELISA and co-localized with Vpr in human cells by
immunofluorescence assay. Interestingly, a large proportion of Vpr-GFP or HA-
tagged Vpr was sequestered in the cytoplasm when co-expressed with this sdAb.
We and others have already observed such phenomenon using sdAb-based
intrabodies [18, 19]. Using an anti-Nef intracellular sdAb, we could efficiently
block most of the activities of this protein [18]. Interestingly, by fusing this sdAb
to a SH3 domain targeting a different epitope of Nef via a flexible linker peptide,
we could block all known activities of HIV-1 Nef [36, 37]. The mechanisms by
which the sdAb induces Vpr delocalization deserve further studies. One possibility
might that the sdAb targets the nuclear localization signal of Vpr, and thus,
inhibits the nuclear import, as it has been shown for phage display-selected scFvs
[38]. Alternatively, the inhibition might be due to steric hindrances generated by
the large size of sdAb-Vpr complex. Surprisingly, this strong effect on Vpr
localization did not translate into an inhibition of two Vpr main functions, i.e.
cytostatic and pro-apoptotic effects. Possible explanations might be that the
residual amount of Vpr remaining in the nucleus is able to induce these effects,
and/or that the Vpr epitope bound by sdAb Vpr1A is not a Vpr epitope involved
in these effects.
Other Y2H studies have selected single-chain antibodies [21, 39], single-chain
intrabodies [40] or even single-domain antibodies [41], but always using nuclear
Y2H. To our knowledge this work is the first to demonstrate that a cytoplasmic
two-hybrid approach in yeast can be used to isolate antibody fragments targeting
intracellular antigens, i.e. intrabodies. Interestingly, bacterial-two-hybrid selec-
tions of sdAb-based intrabodies has recently been reported [42]. However, the
yeast approach brings the possibility of targeting antigens subjected to post-
translational modifications, which increases the chance of isolating intrabodies
recognizing their antigen in their native state in the mammalian cytoplasm.
By using a synthetic Vpr polypeptide to immunize llamas, we successfully
isolated a single domain intrabody able to bind Vpr in the cytoplasm of eukaryotic
cells. One drawback of this approach is the low number of sdAbs selected in this
work. A larger number of positive clones could possibly be achieved by increasing
the size of the original yeast library via larger scale transformation reaction. The
quality of the library is also dependent on the immunization step that could be
improved via the use of immunogenic carrier, especially for small proteins such as
Vpr (13 kDa). Nevertheless, we obtained a sdAb able to interfere with Vpr cellular
localization. To our knowledge, it is the first sdAb and the first intrabody targeting
A Single-Domain Intrabody Targeting HIV-1 Vpr Protein
PLOS ONE | DOI:10.1371/journal.pone.0113729 December 1, 2014 16 / 19
the HIV-1 Vpr protein. This sdAb should be useful as a tool for functional studies
of Vpr and might also help in the design of Vpr inhibitors or even be used as in
vivo tools for therapeutic applications. For example, an innovative bispecific
reagent could be generated by fusing the available anti-Nef intrabody with the
anti-Vpr intrabody generated in this study. Such a construct might be
instrumental in the study of the virus replication and it would be of high interest
to see if such a reagent can efficiently hinder the replication and infection
efficiency of the virus.
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